Low Financial LeverageThe company’s low absolute debt reduces solvency and interest burden risk, preserving financial flexibility. Over a multi-month horizon this conservative leverage profile lowers bankruptcy risk and provides a firmer base to fund clinical development or negotiate non-dilutive financing compared with highly leveraged peers.

Proprietary IDOSE PlatformA differentiated, integrated treatment platform for controlled interstitial PDT is a durable competitive asset. The combination of planning, monitoring and delivery creates higher technical switching costs, supports clinical adoption pathways and positions the company to capture follow-on product or service revenue if regulatory and clinical milestones progress.

Material Equity CushionDespite shrinkage, the current equity base provides a tangible capitalization buffer to support ongoing R&D and regulatory work over the medium term. This larger equity position relative to debt can facilitate staged financing and strategic partnerships without immediate insolvency pressure, aiding sustained development execution.

Bears Say

Minimal Revenue And Deepening LossesThe company remains in a pre-commercial phase with little to no scalable revenue, while operating losses have materially increased. Over the next several months this weak revenue base means the business cannot self-fund growth or absorb fixed costs, prolonging dependence on external capital and increasing execution risk.

Accelerating Negative Free Cash FlowSteepening negative free cash flow signals rising cash burn and shorter operational runway absent financing. This structural cash deficit makes the company more likely to pursue dilutive equity raises or expensive financing, which can constrain strategic options and pressure resources needed for regulatory trials or commercialization efforts.

Erosion Of Shareholder Equity Over TimeThe material decline in equity over several years indicates repeated financing and/or accumulated losses, which dilutes existing owners and reduces the company’s capital buffer. Structurally, persistent equity erosion undermines long-term resilience and can worsen financing terms or investor appetite for future raises.

2OK FAQ

What was SpectraCure AB’s price range in the past 12 months?

SpectraCure AB lowest stock price was €0.00 and its highest was €0.16 in the past 12 months.

What is SpectraCure AB’s market cap?

SpectraCure AB’s market cap is €4.86M.

When is SpectraCure AB’s upcoming earnings report date?

SpectraCure AB’s upcoming earnings report date is May 19, 2026 which is in 76 days.

How were SpectraCure AB’s earnings last quarter?

SpectraCure AB released its earnings results on Feb 19, 2026. The company reported -€0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.002.

Is SpectraCure AB overvalued?

According to Wall Street analysts SpectraCure AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does SpectraCure AB pay dividends?

SpectraCure AB does not currently pay dividends.

What is SpectraCure AB’s EPS estimate?

SpectraCure AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does SpectraCure AB have?

SpectraCure AB has 565,935,670 shares outstanding.

What happened to SpectraCure AB’s price movement after its last earnings report?

SpectraCure AB reported an EPS of -€0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of SpectraCure AB?

Currently, no hedge funds are holding shares in DE:2OK

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

SpectraCure AB

SpectraCure AB (publ) focuses on cancer treatment utilizing laser light sources and photo reactive drugs. It develops IDOSE software with interstitial photodynamic therapy system, which is in Phase II clinical trial for the treatment of solid tumors. The company was founded in 2003 and is based in Lund, Sweden.